Skip to main content

Table 1 Immunization and challenge treatment groups

From: Recombinant tandem epitope vaccination provides cross protection against Actinobacillus pleuropneumoniae challenge in mice

Group

Group name

Number of animals

Immunization

Dose

Challenge

1

PBSC1

6

PBS

100 μg/0.2 mL/per mouse

APP1

2

PBSC5

6

PBS

100 μg/0.2 mL/per mouse

APP5b

3

RTAC1

6

RTA

0.2 mL/per mouse

APP1

4

RTAC5

6

RTA

0.2 mL/per mouse

APP5b

5

IB1-C1

6

inactivated APP1

108 CFU of APP1/0.2 mL/per mouse

APP1

6

IB1-C5

6

inactivated APP1

108 CFU of APP1/0.2 mL/per mouse

APP5b

7

IB5-C1

6

inactivated APP5b

108 CFU of APP5b/0.2 mL/per mouse

APP1

8

IB5-C5

6

inactivated APP5b

108 CFU of APP5b/0.2 mL/per mouse

APP5b

9

RTAIB1 + C1

6

RTA +inactivated APP1

100 μg of RTA + 108 CFU of APP1/0.2 mL/per mouse

APP1

10

RTAIB1 + C5

6

RTA +inactivated APP1

100 μg of RTA + 108 CFU of APP1/0.2 mL/per mouse

APP5b

11

RTAIB5 + C1

6

RTA +inactivated APP5b

100 μg of RTA + 108 CFU of APP5b/0.2 mL/per mouse

APP1

12

RTAIB5 + C5

6

RTA +inactivated APP5b

100 μg of RTA + 108 CFU of APP5b/0.2 mL/per mouse

APP5b

  1. Scheme parameters: first detected the level of antibody; recorded the clinical symptoms and the weight changes of mice; 72 h after infection: dissected the mice and weighed the lungs to calculate the lung index; measured the number of T cells of lung by flow cytometry; measure the cytokine level in serum and BALF of the RTA immunization group